Gregory Covino - Biogen Insider

Chief Accounting Officer, VP of Fin. and Controller

Mr. Gregory F. Covino is Chief Accounting Officer Vice President Finance of Biogen Inc. since April 2012
Age: 49  VP Since 2012      
617-679-2000  http://www.biogen.com

Other Appointments

BIOGENBIOGEN MexicoPresident
Gregory Covino EducationCovino has served as our Vice President, Finance and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporationrationration, a medical device company, as Vice President, Corporationrationrate Analysis and Control since March 2010, having responsibility for the company internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrate Accounting from 1999 to 2002. He received his B.S. in Business Administration from Bryant University.

Management Efficiency

The company has return on total asset (ROA) of 16.4 % which means that it generated profit of $16.4 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 34.18 % meaning that it created $34.18 on every $100 dollars invested by stockholders.
The company currently holds 6.53 B in liabilities with Debt to Equity (D/E) ratio of 0.54 which is about average as compared to similar companies. Biogen Inc has Current Ratio of 3.18 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Filter Other Executives

Custom Filter
Found 7 records

VP Since

Charles MengSciClone Pharmaceuticals Inc
2014
John ThomasAbbott Laboratories
N/A
Michael BoothIncyte Corporation
2015
Min YinSciClone Pharmaceuticals Inc
2011
Paul TrowerIncyte Corporation
2015
Brian MuellerBioMarin Pharmaceutical Inc
2014
Patrick IIICelgene Corporation
N/A

Entity Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. Biogen Inc (BIIB) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 7,350 people. Biogen is listed under Pharmaceutical Products category by Fama And French industry classification and specializes in Healthcare with concentration in Pharmaceuticals And Biosciences.
Did you try this?
Run Financial Widgets Now
   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Hide  View All  Next  Launch Financial Widgets
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Inc to your portfolio
Top Management
Biogen Inc Leadership Team
Michael Ehlers, President, Ph.D
Lynn Schenk, Director
Steven Holtzman, President
Adriana Karaboutis, EVP
Paul Clancy, CFO, MBA
Michel Vounatsos, President, MBA
John Cox, EVP, MBA
Gregory Covino, VP
Paul MBA, CFO
Robert Pangia, Director
Eric Rowinsky, Director, Ph.D
Douglas Williams, EVP
Caroline Dorsa, Director
Stuart Kingsley, EVP
Richard Mulligan, Director
Stelios Papadopoulos, Chairman, Ph.D
George Scangos, CEO, Ph.D
Alexander Denner, Director
Brian Posner, Director
Stephen Sherwin, Director, Ph.D
Susan Alexander, President
Adriana MS, EVP
Kenneth Pietro, President
Tony Kingsley, President, MBA
Matt Griffiths, President
Paul McKenzie, President, Ph.D
Spyros ArtavanisTsakonas, President, Ph.D
Nancy Leaming, Director
Alfred Sandrock, President, Ph.D
Adam Koppel, President, MBA
Stock Performance
Biogen Performance Indicators